Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 14, 2018 - Issue
Submit an article Journal homepage
85
Views
5
CrossRef citations to date
0
Altmetric
Case Report

Efficacy of denosumab therapy for neurofibromatosis type 1 with osteoporosis and history of fractures: a case report

Masashi Uehara1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]
,
Yukio Nakamura1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]Correspondence[email protected]
,
Jun Takahashi1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]
,
Mikio Kamimura2 Center for Osteoporosis and Spinal Disorders, Kamimura Orthopedic Clinic, Kotobuki, Matsumoto, Japan
,
Fumihiro Isobe1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]
,
Tomomi Yamaguchi3 Department of Medical Genetics, Shinshu University School of Medicine, Asahi, Matsumoto, Japan;4 Center for Medical Genetics, Shinshu University Hospital, Asahi, Matsumoto, Japan
,
Tomoki Kosho3 Department of Medical Genetics, Shinshu University School of Medicine, Asahi, Matsumoto, Japan;4 Center for Medical Genetics, Shinshu University Hospital, Asahi, Matsumoto, Japan
,
Shigeharu Uchiyama1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected];5 Department of Orthopedic Surgery, Okaya City Hospital, Honmachi, Okaya, Japan
,
Takako Suzuki1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]
&
Hiroyuki Kato1 Department of Orthopedic Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan, [email protected]
 show all
Pages 1243-1246 | Published online: 16 Jul 2018

References

  • Dunning-DaviesBMParkerAAnnual review of children with neurofibromatosis type 1Arch Dis Child Educ Pract Ed201610110211126486853
  • GómezMBatistaOMolecular diagnosis as a strategy for differential diagnosis and at early ages of neurofibromatosis type 1 (NF1)Rev Med Chil2015143101320133026633276
  • KorfBRDiagnosis and management of neurofibromatosis type 1Curr Neurol Neurosci Rep20011216216711898512
  • TakaharaKKamimuraMNakagawaHUchiyamaSChanges in biochemical markers of bone in patients with insufficiency fracturesJ Bone Miner Metab20042261862515490274
  • Brunetti-PierriNDotySBHicksJGeneralized metabolic bone disease in neurofibromatosis type IMol Genet Metab200894110511118289904
  • TuckerTSchnabelCHartmannMBone health and fracture rate in individuals with neurofibromatosis 1 (NF1)J Med Genet200946425926519066167
  • PetramalaLGiustiniSZinnamoscaLBone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease)Arch Dermatol Res2012304432533122120694
  • HeerväEPeltonenSSvedströmEAroHTVäänänenKPeltonenJOsteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitroBone201250379880322226973
  • HeerväEHuilajaLLeinonenPPeltonenSPeltonenJFollow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 monthsCalcif Tissue Int201494660861224390519
  • BenlidayiICOrtacEAKozanogluERisedronate therapy for neurofibromatosis type 1-related low bone mass: a stitch in time saves nineActa Clin Belg201570213013225338093
  • DiédhiouDCunyTSarrANorou DiopSKleinMWeryhaGEfficacy and safety of denosumab for the treatment of osteoporosis: a systematic reviewAnn Endocrinol (Paris)201576665065726639186
  • KamimuraMNakamuraYIkegamiSUchiyamaSKatoHTaguchiASignificant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patientsOsteoporos Int20172855956627650642
  • WhitakerMGuoJKehoeTBensonGBisphosphonates for osteoporosis: where do we go from here?N Engl J Med2012366222048205122571168
  • VasikaranSEastellRBruyèreOMarkers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standardsOsteoporos Int201122239142021184054

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.